HM CINAC-Puerta del Sur Hospital

If you are the contact person for this centre and you wish to make any changes, please contact us.

SMC participants

Neurologist and clinical researcher in HM CINAC-Puerta del Sur Hospital

Contents related to this centre

A monoclonal antibody called prasinezumab reduces the worsening of motor symptoms in people with Parkinson's disease who have rapidly progressive disease, according to an analysis of a phase 2 clinical trial published in Nature Medicine. These findings suggest that clinical efficacy of prasinezumab, which works by binding to alpha-synuclein protein aggregates, is seen after one year of treatment in such patients. According to the authors, more research is needed to determine whether the antibody can be effective in people with slower disease progression after longer periods of treatment.